Targeting metabotropic glutamate receptor 4 for cancer immunotherapy
Data files
Sep 01, 2021 version files 148.26 MB
-
2020Nov17.8x24_KO-TCR.airr_rearrangement.tsv
-
2020Nov17.8x24_KO-TCR.all_contig_annotations.csv
-
2020Nov17.8x24_KO-TCR.all_contig.fastq
-
2020Nov17.8x24_KO-TCR.clonotypes.csv
-
2020Nov17.8x24_KO-TCR.concat_ref.fasta
-
2020Nov17.8x24_KO-TCR.consensus_annotations.csv
-
2020Nov17.8x24_KO-TCR.consensus.fastq
-
2020Nov17.8x24_KO-TCR.filtered_contig_annotations.csv
-
2020Nov17.8x24_KO-TCR.filtered_contig.fastq
-
2020Nov17.8x24_KO-TCR.metrics_summary.csv
-
2020Nov17.8x24_KO-TCR.web_summary.html
-
2020Nov17.8x24_WT-TCR.all_contig_annotations.csv
-
2020Nov17.8x24_WT-TCR.all_contig.fastq
-
2020Nov17.8x24_WT-TCR.clonotypes.csv
-
2020Nov17.8x24_WT-TCR.concat_ref.fasta
-
2020Nov17.8x24_WT-TCR.consensus_annotations.csv
-
2020Nov17.8x24_WT-TCR.consensus.fastq
-
2020Nov17.8x24_WT-TCR.filtered_contig_annotations.csv
-
2020Nov17.8x24_WT-TCR.filtered_contig.fastq
-
2020Nov17.8x24_WT-TCR.metrics_summary.csv
-
2020Nov17.8x24_WT-TCR.web_summary.html
-
DEG_190406.csv
Abstract
The complex mechanism regulating the immunosuppressive tumor microenvironment (TME) remains poorly understood. Here, we reported a novel role of the metabotropic glutamate receptor-4 (GRM4) in suppressing the anti-tumor immunity. We revealed in three murine syngeneic tumor models (B16, MC38, and 3LL) that either genetic knockout (Grm4−/−) or pharmacological inhibition led to significant delay in tumor growth and synergized with immune checkpoint inhibitors in male mice. Mechanistically, perturbation of GRM4 resulted in a strong anti-tumor immunity by promoting nature killer (NK), CD4+ and CD8+ T cells towards an activated, proliferative, and functional phenotype. Single-cell RNA-sequencing and T Cell Receptor (TCR) profiling further defined the clonal expansion and immune landscape changes in CD8+ T cells. Mechanistically, Grm4-/- intrinsically activated IFN-g production in CD8+ T cells through cAMP/CREB-mediated pathway. Our study appears to be of clinical significance as a signature of NKhigh-GRM4low and CD8high-GRM4low correlated with improved survival in melanoma patients. Therefore, targeting GRM4 could be exploited as a new approach for cancer immunotherapy.
Methods
KO refers to Grm4-/- Mice